...
首页> 外文期刊>Journal of chromatography, B. Analytical technologies in the biomedical and life sciences >Determination of the sulfate and glucuronide conjugates of levornidazole in human plasma and urine, and levornidazole and its five metabolites in human feces by high performance liquid chromatography–tandem mass spectrometry
【24h】

Determination of the sulfate and glucuronide conjugates of levornidazole in human plasma and urine, and levornidazole and its five metabolites in human feces by high performance liquid chromatography–tandem mass spectrometry

机译:高效液相色谱 - 串联质谱法测定人血浆和尿液中Levornidazole的硫酸盐和葡萄糖酮缀合物及左半唑及其五种代谢物

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Levornidazole is a novel third-generation nitroimidazoles antibiotic which metabolism and disposition in human are not well known. We have previously developed two methods to quantify levornidazole and its phase I metabolites, Ml (Hydroxylation metabolite), M2 (N-dealkylation metabolite) and M4 (Oxidative dechlorination metabolite), in human plasma and urine. In this study, we developed three novel liquid chromatographic-tandem mass spectrometric (LC-MS/MS) methods and analyzed its phase II metabolites, sulfate conjugate (M6) and glucuronide conjugate (M16), in human plasma and urine, and the parent drug and above-mentioned five metabolites in human feces samples. Analytes and internal standard (IS) in human plasma were extracted by a solid-phase extraction procedure and separated on an ACQUITY UPLC CSH C18 column in gradient elution using acetonitrile and 0.1% formic acid aqueous solution as the mobile phase. The pretreatment procedures for urine and feces homogenate samples involved a protein precipitation followed by liquid-liquid extraction, and chromatographic separations were performed on the Atlantis T3 columns of different lengths and particle sizes (2.1?×?50?mm, 3?μm and 2.1?×?150?mm, 5?μm), respectively. The mobile phases consisted of formic acid and acetonitrile-methanol solution (v/v, 50:50) in gradient elution. The MS/MS analysis was conducted on TSQ Quantum triple quadrupole mass spectrometer using electrospray ionization with selected reaction monitoring (SRM) in the positive ion mode. The calibration curves for all analytes were linear and the validation ranges were as follows: 0.005–0.500?μg/mL for M6 and 0.005–2.500?μg/mL for M16 in plasma; 0.010–10.000?μg/mL for M6 and M16 in urine; 0.005–1.000?μg/mL for levornidazole, M2, M4 and M16, and 0.010–2.000?μg/mL for M1 and M6 in human feces homogenate. Across these matrices, mean intra- and inter- batch accuracy values were in the ranges of 80.0%–120.0%, and intra- and inter-batch precision values did not exceed 20%. It was fully validated including selectivity, linearity, matrix effect, extraction recovery, stability, dilution integrity, carryover and incurred sample analysis (ISR). These newly developed methods were successfully applied in pharmacokinetics, metabolism and disposition study of levornidazole in 12 healthy Chinese subjects.
机译:Levornidazole是一种新型的第三代Nitroimidazoles抗生素,其在人类中的代谢和置性是不公知的。我们之前已经开发出两种方法来量化Levornidazole及其相I代谢物,ML(羟基化代谢物),M2(N-脱烷基化代谢物)和M4(氧化脱氯代谢物),在人血浆和尿液中。在这项研究中,我们开发了三种新型液相色谱 - 串联质谱(LC-MS / MS)方法,并分析了其II代谢物,硫酸酯缀合物(M6)和葡糖醛酸缀合物(M16),在人血浆和尿液中,以及父母药物和上述人类粪便样品中的五种代谢物。通过固相萃取程序提取人血浆中的分析物和内标(IS),并在梯度洗脱的Acquity UPLC C18柱上分离使用乙腈和0.1%甲酸水溶液作为流动相。尿液和粪便匀浆样品的预处理程序涉及蛋白质沉淀,然后进行液 - 液萃取,并在不同长度的寰椎T3柱上进行色谱分离(2.1××50Ωmm,3?μm和2.1 ××150?mm,5?μm)。移动相在梯度洗脱中由甲酸和乙腈 - 甲醇溶液(v / v,50:50)组成。在正离子模式下使用电喷雾电离在TSQ量子三倍四极杆质谱仪上进行MS / MS分析。所有分析物的校准曲线是线性的,并且验证范围如下:0.005-0.500Ωμg/ ml,用于M6和0.005-2.500Ω·μg/ ml在等离子体中的M16; 0.010-10.000?尿液中m6和m16的0.010-10.000?μg/ ml;对于Levornidazole,M2,M4和M16,M1和M6的Levornidazole,M2,M4和M16,M1和M6中的0.005-1.000×μg/ ml。在这些矩阵中,平均值和间歇性精度值在80.0%-120.0%的范围内,并且批量间精度值不超过20%。它完全验证,包括选择性,线性度,基质效应,提取回收,稳定性,稀释完整性,携带和发生的样品分析(ISR)。这些新开发的方法成功地应用于12个健康的中国受试者的左甲唑的药代动力学,代谢和处置研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号